A Randomized Trial of Sequenced Treatment Using Placebo Without Deception Followed by Open-Label Antidepressant Versus Immediate Open-Label Antidepressant Treatment for Major Depressive Disorder
Overview
- Phase
- Not Applicable
- Intervention
- Duloxetine
- Conditions
- Major Depressive Disorder
- Sponsor
- Sunnybrook Health Sciences Centre
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- >= 50% improvement in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (MADRS Response)
- Status
- Terminated
- Last Updated
- 11 years ago
Overview
Brief Summary
In recent years, there has been growing evidence that antidepressants are only marginally effective compared to placebo for mild to moderate depression. In other words, although many people improve when they take antidepressant medications, almost as many get better with placebo pills. One possible solution to this problem would be to give patients a trail of a placebo prior to giving them an antidepressant, however there are ethical issues with doing this deceptively. New evidence from other placebo-responsive disorders such as irritable bowel syndrome shows that people may benefit from placebos even if they know they are taking them. This study aims to determine whether giving placebos without deception to people with major depressive disorder followed by the option to switch to an antidepressant is an effective strategy. There will be 3 groups of subjects. The first group is a standard treatment arm and will receive duloxetine, an antidepressant. The second will be given a placebo with the option to switch to duloxetine if they do not improve. The third group will receive supportive clinical visits the option to switch to duloxetine if they do not improve. This design will allow us to determine whether a sequenced treatment of a placebo without deception and then the option to switch to an antidepressant is a viable strategy. It will also help us to determine to what degree the benefit comes from the ritual of receiving and taking the placebo tablet versus the benefit of visits with a doctor alone. The primary hypothesis is that there will be a less than 5% difference between response rates after 12 weeks in the sequenced placebo-then-antidepressant treatment group (both subjects who have remained on placebo as well as those who have switched to the antidepressant will be considered as one group) compared to the immediate antidepressant therapy group.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Provision of written informed consent
- •Diagnosis of major depressive disorder, currently depressed as determined by DSM-IV diagnostic criteria (confirmed using the MINI)
- •Both females and males, aged 18 to 65 years
- •Outpatient status
- •Female patients of childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test at enrolment and must be taking or willing to take some acceptable form of birth control during the course of the study if they are or plan to be sexually active
- •A grade 8 English comprehension, the ability to understand and comply with the requirements of the study and capable of providing informed consent
- •17-item Hamilton Depression Rating Scale (HAM-D) score of 14-22 at screening and at baseline
Exclusion Criteria
- •Diagnosis of a past hypomanic, manic or mixed state.
- •Current or past psychotic symptoms
- •Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria
- •Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrolment
- •Any pervasive developmental disorder (according to DSM-IV criteria)
- •Diagnosis of dementia (according to DSM-IV criteria)
- •Is at significant risk for suicide, as defined by a score of ≥ 2 on the suicide item of the MADRS, any suicidal ideation with intent or a plan within the 3 months prior to study entry or in the opinion of the investigator.
- •Any history of lifetime suicide attempts
- •Current treatment with an antidepressant medication
- •Treatment with an antipsychotic, mood stabilizer or other psychoactive medication within a period of 5 half-lives of the medication prior to baseline visit
Arms & Interventions
Open-label duloxetine
12 week treatment with duloxetine
Intervention: Duloxetine
Open-label Placebo
4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
Intervention: placebo
Supportive clinical management
4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
Intervention: Study visits only
Outcomes
Primary Outcomes
>= 50% improvement in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (MADRS Response)
Time Frame: 12 weeks
Secondary Outcomes
- MADRS remission(12 weeks)
- Credibility and Expectancy Scale (CES)(Baseline)